CRL

Business profile & competitive position

Charles River Laboratories International, Inc. is classified in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. Operationally, it describes itself as a full-service, non-clinical global drug development partner. Its work spans research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing support products and services that take clients from target identification through non-clinical development and product release. The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue was $4.0 billion, with DSA contributing 59.8%, RMS 21.1%, and Manufacturing 19.1%. It currently runs more than 120 sites across more than 20 countries.

The financial profile, however, does not currently show wide-moat profitability. For the period reflected in the supplied snapshot, the net margin is –6.0% and return on equity is –7.7%. Those negative figures mean the company’s most recent trailing earnings are a loss, so any claim of durable pricing power cannot be supported purely by these margins. What the data do support is a scale-based and integrated competitive position: a geographically broad footprint, a diversified service portfolio, and the January 2026 acquisition of certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. In other words, CRL’s moat today appears to rest on breadth, integration, and supply-chain access rather than on near-term margin dominance.

Financial posture

Charles River Laboratories currently carries a market capitalization of $14.1 billion. The headline valuation ratio is a P/E of –60.6, driven by negative trailing earnings. That same loss-making posture shows up in the net margin of –6.0% and an ROE of –7.7%. Investors should read these metrics as a profitability reset rather than a conventional earnings-based valuation: a negative P/E is mathematically a consequence of losses, not a premium multiple.

The stock’s beta is 1.41, indicating it has moved materially more than the broad market and is likely to remain sensitive to risk appetite in healthcare/biotech spending. As of the October 5, 2026 snapshot, the price was $293.29, with a 50-day exponential moving average of $272.68 and a relative strength index of 57.2. That places the stock slightly above its 50-day EMA and in neutral RSI territory, but these are descriptive observations, not directional recommendations.

Strategic priorities & outlook

According to its most recent 10-K strategic disclosure, Charles River’s near-term priorities are centered on footprint optimization and organizational integration. The company plans to close or consolidate approximately 12 additional sites over the next two years, principally in the DSA and RMS segments. It is also integrating Discovery Services and Safety Assessment into one overarching DSA organization, combining the sales force and leadership structure under a single umbrella.

Beyond restructuring, the stated objective is to become the scientific partner of choice by delivering a comprehensive and integrated portfolio to accelerate biomedical research and therapeutic innovation. A related priority is expanding Biologics Testing Solutions service offerings and facilities in both the U.S. and Europe. These priorities line up with the 2025 revenue split, in which DSA is already nearly 60% of the business, suggesting that execution in the DSA segment is the central swing factor for the next 12–24 months.

Macro & geopolitical exposure

Because CRL sits in Healthcare/Medical – Diagnostics & Research, its macro exposures follow from the non-clinical drug-development value chain rather than from hospital or direct-patient revenue. Regulation is a core exposure: GLP compliance, FDA/EMA inspections, and animal-welfare standards all affect its safety-assessment and research-model businesses. Trade policy matters because the supply chain includes live and specialized research models; the January 2026 Cambodia acquisition is consistent with an industry where primate sourcing and cross-border logistics can be politically and ethically sensitive.

Currency risk is also relevant for a company operating in more than 20 countries, and revenue growth can correlate with biotech/pharma R&D budgets, which in turn depend on capital-market conditions and interest rates. Input costs for animal husbandry, transportation, and specialized laboratories create additional operational sensitivity broadly typical of the diagnostics and research-services industry.

Recent developments

• September 30, 2026 (defenseworld.net): “Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Consensus Price Target of $290.00 According to Analysts.” This is an informational market-data item, not an investment recommendation.
• September 25, 2026 (marketbeat.com): “Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan.” The 5%–7% growth target and $300 million savings figure came from the company’s refreshed 2030 plan presentation.
• September 24, 2026 (seekingalpha.com): “Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript.” Management laid out the refreshed strategic vision to investors.
• September 24, 2026 (businesswire.com): “Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day.” This reinforces the 2030-plan messaging and the integration/optimization priorities discussed in the 10-K.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, CRL has beaten the published EPS estimate in all eight quarters, a 100% beat rate, with an average earnings surprise of 9.3%. The average 5-day post-earnings price move across those quarters is +1.24%, classified as an upward drift. The next scheduled report is November 4, 2026, before the market open, with the current consensus EPS estimate at $2.97.

Looking at the most recent four quarters shows that the positive average masks wide dispersion:

• August 5, 2026: actual EPS $3.02 vs. estimate $2.74 (10.2% surprise, beat); the stock rose 1.84% the next day and 9.07% over the following five days.
• May 7, 2026: actual EPS $2.06 vs. estimate $1.96 (5.1% surprise, beat); the stock fell 2.23% the next day and 12.42% over the following five days.
• February 18, 2026: actual EPS $2.39 vs. estimate $2.33 (2.6% surprise, beat); the stock rose 3.95% the next day and 6.05% over the following five days.
• November 5, 2025: actual EPS $2.43 vs. estimate $2.32 (4.7% surprise, beat); the stock rose 1.9% the next day and 2.27% over the following five days.

The practical takeaway is that CRL has consistently cleared the official and unofficial consensus, yet the post-earnings price reaction has ranged from strongly positive to sharply negative even on beats. That pattern suggests the market’s real expectation includes more than just the headline EPS number—guidance, segment margin trajectory, and strategic execution all appear to influence the post-earnings price path.